Taysha Gene Therapies Inc
NASDAQ:TSHA 3:58:04 PM EDT
Products, Other Pre-Announcement
Taysha Gene Therapies Provides Update On Tsha-120 Program In Giant Axonal Neuropathy
Published: 01/31/2023 22:32 GMT
Taysha Gene Therapies Inc (TSHA) - Taysha Gene Therapies Provides Update on Tsha-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook.
Taysha Gene Therapies Inc-submission of Cta to United Kingdom Mhra for Tsha-102 in Pediatric Patients With Rett Syndrome Expected in Mid-2023.
Taysha Gene Therapies Inc-submission of an Investigational New Drug Application for Tsha-102 for Rett Syndrome to FDA Planned in H2 2023.
Taysha Gene -fda Acknowledged Mfm32 As Acceptable Endpoint With Recommendation to Dose Additional Patients in Double-blind, Placebo-controlled Design.
Taysha Gene Therapies Inc-submission of Cta to United Kingdom Mhra for Tsha-102 in Pediatric Patients With Rett Syndrome Expected in Mid-2023.
Taysha Gene Therapies Inc-submission of an Investigational New Drug Application for Tsha-102 for Rett Syndrome to FDA Planned in H2 2023.
Taysha Gene -fda Acknowledged Mfm32 As Acceptable Endpoint With Recommendation to Dose Additional Patients in Double-blind, Placebo-controlled Design.